Grail survives adcomm vote it now awaits fda decision cancer blood test

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 24 Sept, 13:15 UTC

Despite a major trial setback earlier this year and increasing questions over its efficacy, medtech Grail has beaten the odds and seen a positive recommendation for its multi-cancer blood test Galleri from FDA advisors.

science

Sources

• T2Grail survives adcomm vote it now awaits fda decision cancer blood testFierce Biotech / Fierce Healthcare / MedCity / GEN24 Sept, 13:15